Hydrogel Treatment for Atopic Dermatitis Receives FDA Clearance
The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for Zabalafin Hydrogel, a novel therapy designed to treat mild to moderate atopic dermatitis (AD) comprehensively.